{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '10.3.1', 'Temporary treatment discontinuation with investigational medicinal product(s)', '75', '10.3.2', 'Permanent treatment discontinuation with investigational medicinal product(s)', '76', '10.3.3', 'List of criteria for permanent treatment discontinuation', '76', '10.3.4', 'Handling of patients after permanent treatment discontinuation', '76', '10.3.5', 'Procedure and consequence for patient withdrawal from study', '77', '10.4', 'OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING', '77', '10.4.1', 'Definitions of adverse events', '77', '10.4.1.1', 'Adverse event', '77', '10.4.1.2', 'Serious adverse event', '77', '10.4.1.3 Adverse event of special interest', '78', '10.4.2', 'Serious adverse events waived from expedited regulatory reporting to regulatory', 'authorities', '80', '10.4.3', 'General guidelines for reporting adverse events', '80', '10.4.4', 'Instructions for reporting serious adverse events', '81', '10.4.5', 'Guidelines for reporting adverse events of special interest', '81', '10.4.6', 'Guidelines for management of specific laboratory abnormalities', '81', '10.4.7', 'Guidelines for reporting product complaints (IMP/NIMP/device)', '82', '10.5', 'OBLIGATIONS OF THE SPONSOR', '83', '10.6', 'SAFETY INSTRUCTIONS', '83', '10.7', 'ADVERSE EVENTS MONITORING', '83', '11', 'STATISTICAL CONSIDERATIONS', '84', '11.1', 'DETERMINATION OF SAMPLE SIZE', '84', '11.2', 'DISPOSITION OF PATIENTS', '84', '11.3', 'ANALYSIS POPULATIONS', '84', '11.3.1', 'Modified Intent-to-treat population', '84', '11.3.2', 'Safety population:', '85', '11.4', 'STATISTICAL METHODS', '85', '11.4.1', 'Extent of study treatment exposure', '85', '11.4.2', 'Analyses of efficacy endpoints', '86', '11.4.2.1 Analysis of primary efficacy endpoint', '86', '11.4.2.2 Analyses of secondary efficacy endpoints', '86', '11.4.2.3 Multiplicity considerations', '86', '11.4.3', 'Analyses of safety data', '87', '11.4.3.1', 'Adverse events', '87', '11.4.3.2 Laboratory safety variables', '87', '11.4.3.3 Physical examination and vital signs', '88', 'Property of the Sanofi Group - strictly confidential', 'Page 25', 'VV-CLIN-0254406 5 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '11.4.3.4 Other safety endpoints', '88', '11.4.4', 'Analyses of pharmacokinetic and pharmacodynamic variables', '88', '11.4.5', 'Analyses of exploratory endpoints', '89', '11.5', 'INTERIM ANALYSIS', '89', '12', 'ETHICAL AND REGULATORY CONSIDERATIONS', '90', '12.1', 'ETHICAL AND REGULATORY STANDARDS', '90', '12.2', 'INFORMED CONSENT', '90', '12.3', 'HEALTH AUTHORITIES AND INSTITUTIONAL REVIEW BOARD/INDEPENDENT', 'ETHICS COMMITTEE', '91', '13', 'STUDY MONITORING', '92', '13.1', 'RESPONSIBILITIES OF THE INVESTIGATOR(S)', '92', '13.2', 'RESPONSIBILITIES OF THE SPONSOR', '92', '13.3', 'SOURCE DOCUMENT REQUIREMENTS', '93', '13.4', 'USE AND COMPLETION OF ELECTRONIC CASE REPORT FORMS AND ADDITIONAL', 'REQUEST', '93', '13.5', 'USE OF COMPUTERIZED SYSTEMS', '93', '14', 'ADDITIONAL REQUIREMENTS', '94', '14.1', 'CURRICULUM VITAE', '94', '14.2', 'RECORD RETENTION IN STUDY SITES', '94', '14.3', 'CONFIDENTIALITY', '94', '14.4', 'PROPERTY RIGHTS', '95', '14.5', 'DATA PROTECTION', '95', '14.6', 'INSURANCE COMPENSATION', '95', '14.7', 'SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES', '96', '14.8', 'PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF', 'A SITE', '96', '14.8.1', 'By the Sponsor', '96', '14.8.2', 'By the Investigator', '97', '14.9', 'CLINICAL TRIAL RESULTS', '97', '14.10', 'PUBLICATIONS AND COMMUNICATIONS', '97', 'Property of the Sanofi Group - strictly confidential', 'Page 26', 'VV-CLIN-02544065.0']\n\n###\n\n", "completion": "END"}